PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

Comparison of circulating tumor cell (CTC) detection rates with epithelial cell adhesion molecule (EpCAM) and cell surface vimentin (CSV) antibodies in different solid tumors: a retrospective study

(2021) Yang Gao et al.   PeerJ

Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

(2021) Mio Ikeda et al.   Cancers

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma

(2021) Liting Zhong et al.   Frontiers in Oncology

Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer

(2021) Xiaohong Xie et al.   Frontiers in Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

(2021) Zhenggang Ren et al.   LANCET ONCOLOGY

Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer

(2021) Jianghua Wu et al.   MODERN PATHOLOGY

Low Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

(2021) Fernanda G Herrera et al.   Cancer Discovery

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer

(2021) Ioannis Zerdes et al.   Cancers

Immunotherapies for hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

Prognostic significance of PD‐L1 expression on cell‐surface vimentin‐positive circulating tumor cells in gastric cancer patients

(2020) Mengyuan Liu et al.   Molecular Oncology

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial

(2020) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer

(2019) Tao Wei et al.   CANCER LETTERS

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

(2019) Melanie Janning et al.   Cancers

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma

(2019) Jeong Il Yu et al.   Cancer Medicine

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study

(2019) Muhammad A. Khattak et al.   ONCOLOGIST

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer

(2018) Galatea Kallergi et al.   Therapeutic Advances in Medical Oncology

Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience

(2018) Mohammed Salhab et al.   Journal for ImmunoTherapy of Cancer

Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems

(2016) Po-Hong Liu et al.   JOURNAL OF HEPATOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma

(2016) Sun Ju-Xian et al.   Cancer Biology & Medicine

Frequent expression of PD-L1 on circulating breast cancer cells

(2015) Martine Mazel et al.   Molecular Oncology

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology